34,35 However, the controversy surrounding the possible benefits of GIPR agonism stems from two main observations: its impaired insulinotropic effects, 36,37 and the prevention of weight gain by suppression of endogenous GIP-induced adipogenesis, 38,39 However, these seemingly discouraging observations have been questioned by the finding of the central anorexic effects of GIP, 4042 and benefits of the GLP-1R/GIPR dual agonist LY3298176 (tirzepatide) in diabetic and overweight individuals
Askarpour M, Hadi A, Dehghani Kari Bozorg A, Sadeghi O, Sheikhi A, Kazemi M, Ghaedi E
Obesity is a well-established major risk factor for metabolic disorders including diabetes
is funded by the National Institutes of Heath, the National Multiple Sclerosis Society, The Dana Foundation and the Maisin Foundation
Batch Tested & Verified Consistent analytical verification standards per batch
Retrieved from Rippe, J